Sight-saving drug to be offered to premature babies, announces NHS
The NHS screens babies for the condition retinopathy of prematurity
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Premature babies across England will be offered a sight-saving drug, the NHS has announced.
Retinopathy of prematurity (ROP) is an eye disease that can occur among babies who are born early or those born with a low birth weight.
The NHS routinely screens these babies for the condition, which affects blood vessels in the retina, creating damaging scar tissue and causing blindness.
Traditionally the condition is treated with laser eye surgery but some babies are too unwell or fragile to have the treatment.
Now the NHS is offering new “life-changing” drug ranibizumab to babies with ROP across England who are unable to receive traditional treatment.
Around 20 babies a year will benefit, it is estimated.
The drug is already routinely used in adults with wet age-related macular degeneration.
It works by temporarily stopping the action of a growth protein called vascular endothelial growth factor, which reduces or reverses the growth of the abnormal blood vessels.
NHS chief executive Amanda Pritchard said: “The impacts of vision loss can be absolutely devastating, particularly for children and young people, so it’s fantastic that this treatment will now give families across the country another life-changing option to help save their child’s precious sight.
“The national roll-out of this lifeline treatment for babies who are too poorly to undergo laser therapy is a vital step forward in preventing avoidable vision loss, and as we prepare to mark our 75th anniversary this is another example of how the NHS continues to ensure that the latest and most effective treatments are available for everyone who needs them.”
One mother described how “lucky” her daughter was to have the treatment. Millie Swan, from Surrey, was born prematurely at 23 weeks.
She spent five months in hospital and developed retinopathy of prematurity.
When she was three months old the condition became so severe in her left eye that she needed urgent treatment to save her sight.
Millie’s mother Natalie said: “She was meant to have laser treatment, which is the usual way to treat this condition, but when they gave her the sedative to prepare her for the procedure she didn’t tolerate it at all so they couldn’t start the procedure.
“At this point we thought she would end up blind in her left eye but we were lucky enough to get offered this new treatment, which was an injection into the eye.
“Millie will be three years old in July and her eyesight is now normal and she enjoys looking at the pictures in her books and aeroplanes in the sky.
“We feel so lucky that she got to have this procedure and avoided almost certain blindness in that eye – and now other families will be able to benefit from it too.”